Summary
Background Sepsis has no proven specific pharmacologic treatment. Reported mortality in sepsis ranges from 30%–45%. This study was designed to determine the safety preliminary efficacy of allogenic apoptotic cells administered for immunomodulation in septic patients.
Methods The primary aim of this phase IB study was to determine the safety profile of apoptotic cell infusion in subjects presenting to the emergency room with sepsis. Sepsis was determined by clinical infections and Sequential Organ Failure Assessment (SOFA) scores >2. The secondary aims were to measure organ dysfunction, intensive care unit (ICU) and hospital stays, and mortality, that were compared to historical controls. Exploratory endpoints included measuring immune modulator agents to elucidate the mechanism of action using Luminex® analysis.
Findings Ten patients were treated with apoptotic cells, administered as a single dose or two sequential doses. All 10 patients had mild-to-moderate sepsis with a SOFA score range of 2–6 upon entering the study. No serious adverse events (SAEs) and no related AEs were reported. All 10 study subjects survived while matched historical controls had a mortality rate of 27%. The study subjects exhibited rapid resolution of organ dysfunction and had significantly shorter ICU lengths of stay compared to matched historical controls (p<0·0001). All patients had both elevated pro- and anti-inflammatory cytokines, chemokines and additional immune modulators that gradually decreased following treatment.
Interpretation Administration of apoptotic cells to patients with mild-to-moderate sepsis was safe and had a significant immuno-modulating effect, leading to early resolution of the cytokine storm.
Trial registration ClinicalTrials.gov Identifier: NCT03925857
Funding The study was sponsored by Enlivex Therapeutics Ltd.
Competing Interest Statement
PV van Heerden received honoraria from Enlivex Ltd as a consultant. D Mevorach is the founder, and CMO of Enlivex Therapeutics Ltd.; Y Shabat and B Reicher are part of the research team of Enlivex Therapeutics Ltd. Enlivex Therapeutics administration was not involved in writing the manuscript.
Clinical Trial
NCT03925857
Funding Statement
The study was sponsored by Enlivex Therapeutics Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Human Subjects Review Board of The Helsinki Committee, Hadassah Medical Organisation, Jerusalem, Israel. Approval number: HMO-0152-18.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: PV van Heerden received honoraria from Enlivex Ltd as a consultant. D Mevorach is the founder, and CMO of Enlivex Therapeutics Ltd.; Y Shabat and B Reicher are part of the research team of Enlivex Therapeutics Ltd. Enlivex Therapeutics administration was not involved in writing the manuscript.
Data Availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request
